HEK293 |
Function assay |
|
|
|
Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay |
16680159 |
HEK293 |
Function assay |
|
|
|
Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay |
16680159 |
HEK293 |
Function assay |
|
|
|
Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay |
16680159 |
HEK293 |
Function assay |
|
|
|
Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay |
16680159 |
HEK293 |
Function assay |
|
|
|
Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay |
16680159 |
MG63 |
Function assay |
1 uM |
1 hr |
|
Increase in lactate production in MG63 cells at 1 uM after 1 hr by ELISA |
17088489 |
U937 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay, IC50=0.07μM |
17158054 |
U937 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay, IC50=0.2μM |
17158054 |
U937 |
Antiproliferative assay |
|
24 hrs |
|
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay, IC50=13μM |
17158054 |
HT1080 |
Function assay |
|
|
|
Inhibition of proMMP2 production in human HT1080 cells by gelatin zymography analysis |
17158054 |
HT1080 |
Function assay |
|
|
|
Inhibition of proMMP9 production in human HT1080 cells by gelatin zymography analysis |
17158054 |
neural precursor cells |
Function assay |
|
|
|
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
17417631 |
HepG2 |
Antitumor assay |
|
24 hrs |
|
Antitumor activity against human HepG2 cells after 24 hrs by MTT assay, ED50=15μM |
17482824 |
A549 |
Antitumor assay |
|
24 hrs |
|
Antitumor activity against human A549 cells after 24 hrs by MTT assay, ED50=26μM |
17482824 |
N548 |
Cell death rescue assay |
|
|
|
Cell death rescue in rat striatal neuron N548 mutant cells, EC50=0.5μM |
17726098 |
ASH neuronal cells |
Cell death rescue assay |
|
|
|
Cell death rescue of ASH neuronal cells in Caenorhabditis elegans Huntington's disease model, EC50=2μM |
17726098 |
neuronal cells |
Cell death rescue assay |
|
|
|
Cell death rescue of neuronal cells in drosophila Huntington's disease model, EC50=10μM |
17726098 |
N548 |
Toxicity assay |
|
|
|
Toxicity in rat striatal neuronal N548 mutant cells, TC50=40μM |
17726098 |
N548 |
Cell death rescue assay |
|
|
|
Suppression of cell death in rat striatal neuronal N548 mutant cells assessed as suppression of caspase 7 activation by Western blotting |
17726098 |
N548 |
Activation of ERK in |
10 uM |
|
|
Activation of ERK in rat striatal neuronal N548 mutant cells at 10 uM by Western blotting |
17726098 |
N548 |
Activation of AKT in |
10 uM |
|
|
Activation of AKT in rat striatal neuronal N548 mutant cells at 10 uM by Western blotting |
17726098 |
N548 |
Activation of ERK in |
50 uM |
|
|
Activation of ERK in rat striatal neuronal N548 mutant cells at 50 uM by Western blotting |
17726098 |
N548 |
Activation of AKT in |
50 uM |
|
|
Activation of AKT in rat striatal neuronal N548 mutant cells at 50 uM by Western blotting |
17726098 |
N548 |
Activation of AKT in |
10 uM |
6 hrs |
|
Activation of AKT in DNA-deficient rat striatal neuronal N548 mutant cells at 10 uM after 6 hrs by Western blotting |
17726098 |
N548 |
Cell death rescue assay |
|
|
|
Cell death rescue in rat striatal neuronal N548 mutant cells by calcein acetoxymethyl ester assay |
17726098 |
N548 |
Cell death rescue assay |
10 uM |
7 days |
|
Cell death rescue in rat striatal neuronal N548 mutant cells analysed every day for 7 days at 10 uM by trypan blue dye-exclusion assay |
17726098 |
N548 |
Cell death rescue assay |
|
|
|
Suppression of cell death in rat striatal neuronal N548 mutant cells assessed as suppression of caspase 3 activation by Western blotting |
17726098 |
N548 |
Cell death rescue assay |
10 uM |
|
|
Cell death rescue in DNA-deficient rat striatal neuronal N548 mutant cells at 10 uM |
17726098 |
U373 MG |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human U373 MG cells after 72 hrs |
18513974 |
T47D |
Function assay |
0.001 to 0.1 uM |
|
|
Inhibition of cellular respiration in human T47D cells assessed as rate of oxygen consumption at 0.001 to 0.1 uM |
21875114 |
T47D |
Function assay |
|
48 hrs |
|
Reduction in ATP level in human T47D cells after 48 hrs by HPLC-UV analysis |
21875114 |
T47D |
Function assay |
0.01 to 0.1 uM |
72 hrs |
|
Reduction in ATP level in human T47D cells at 0.01 to 0.1 uM after 72 hrs by HPLC-UV analysis |
21875114 |
T47D |
Function assay |
0.1 to 1 uM |
30 mins |
|
Inhibition of mTOR in human T47D cells assessed as eIF2alpha hyperphosphorylation on Ser 51 at 0.1 to 1 uM after 30 mins by Western blotting |
21875114 |
T47D |
Function assay |
0.1 to 1 uM |
30 mins |
|
Inhibition of mTOR in human T47D cells assessed as eEF2 hyperphosphorylation on Ser 56 at 0.1 to 1 uM after 30 mins by Western blotting |
21875114 |
MDA-MB-231 |
Function assay |
0.1 to 1 uM |
30 mins |
|
Inhibition of mTOR in human MDA-MB-231 cells assessed as eIF2alpha hyperphosphorylation on Ser 51 at 0.1 to 1 uM after 30 mins by Western blotting |
21875114 |
MDA-MB-231 |
Function assay |
0.1 to 1 uM |
30 mins |
|
Inhibition of mTOR in human MDA-MB-231 cells assessed as eEF2 hyperphosphorylation on Ser 56 at 0.1 to 1 uM after 30 mins by Western blotting |
21875114 |
MDA-MB-231 |
Function assay |
0.01 to 0.1 uM |
48 hrs |
|
Reduction in ATP level in human MDA-MB-231 cells at 0.01 to 0.1 uM after 48 hrs by HPLC-UV analysis |
21875114 |
697 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human 697 cells after 72 hrs by MTS assay, IC50=0.3μM |
23895019 |
697 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human 697 cells after 48 hrs by MTS assay, IC50=0.3μM |
23895019 |
HT-29 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay, IC50=0.3μM |
23895019 |
Hepa-1c1c7 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against mouse Hepa-1c1c7 cells, IC50=0.7μM |
23895019 |
Hepa1c1c7 |
Function assay |
|
|
|
Induction of quinone reductase in mouse Hepa1c1c7 cells, CD=0.8μM |
23895019 |
Raji |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human Raji cells after 72 hrs by MTS assay, IC50=1.1μM |
23895019 |
Raji |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human Raji cells after 48 hrs by MTS assay, IC50=4.2μM |
23895019 |
TA3/Ha |
Function assay |
12 uM |
|
|
Induction of NAD(P)H oxidation in mouse TA3/Ha cells assessed as reduction of NAD(P)H/NAD(P)+ ratio at 12 uM by spectrofluorometer analysis |
24568614 |
L5178Y |
Cytotoxicity assay |
|
|
|
Cytotoxicity against mouse L5178Y cells by MTT assay, IC50=0.3μM |
28075580 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells |
29435139 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells |
29435139 |
fibroblast cells |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells |
29435139 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay, IC50=1.52μM |
30613327 |
DLD1 |
Function assay |
|
|
|
Inhibition of mitochondrial oxidative phosphorylation in human DLD1 cells assessed as reduction in oxygen consumption rate by seahorse XFe96 analyser based assay |
31774672 |